phase readout
saveNCT07460206: Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment
NOT_YET_RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica. Phase: PHASE2. Conditions: ccRCC
view source ↗
comments(0)
5-min edit window · permanent after that